Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Real World Evidence, Lymphoid Malignancies
Type: Oral
Hematology Disease Topics & Pathways:
Epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Real World Evidence, Lymphoid Malignancies
Sunday, December 12, 2021: 4:30 PM-6:00 PM
Hall A1
(Georgia World Congress Center)
Moderators:
Juan Du, MD, PhD, Shanghai Changzheng hospital, Naval Medical University
and
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami
Disclosures:
Landgren: Amgen: Honoraria, Research Funding; Janssen: Honoraria, Other, Research Funding; Celgene: Research Funding; BMS: Research Funding; Adaptive Biotech: Honoraria; Theradex: Other: IDMC.
The current state of the definitions for multiple myeloma and related precursor conditions include a range of unresolved clinical and scientific questions. Many of these questions can be studied in larger retrospective databases, clinical epidemiology cohort studies, or smaller molecular studies with clinically well-annotated samples.
Dr. Burgos will present results from over 5000 cases with monoclonal gammopathies investigated by flowcytometry. Their study shows how an algorithm which can be installed in clinical flow cytometry software can be used to generate automated classifications across the spectrum of monoclonal gammopathies.
Dr. Long will discuss how current reference intervals for serum free light-chain (FLC) and FLC-ratio are inaccurate for patients with decreased kidney function. Based on the large prospective iStopMM study, new reference intervals will be proposed for serum FLC and FLC-ratio, for use in patients with chronic kidney disease which also seem to be accurate in patients on dialysis.
Dr. Visram will address that current smoldering multiple myeloma (SMM) prognostication models - routinely used in clinical practice - indeed were developed for use at diagnosis. This talk will focus on how one dynamically can risk stratify patients post-diagnosis, and how to better identify patients with evolving disease.
Dr. Puig will discuss comparisons of blood based immunofixation electrophoresis (IFE), quantitative immunoprecipitation mass spectrometry, liquid chromatography mass spectrometry (LC-MS), and bone marrow-based MRD assays. Focus of the investigations include capacity to identify the presence of disease and ability to determine prognosis.
Dr. Samur will present results from their studies designed to distinguish genomic hallmarks of low-risk (vs high-risk) smoldering multiple myeloma. Using transcriptome, epigenome and whole genome profiling they have interrogated samples from patients with clinical follow-up data.
Dr. Jelinek will discuss findings from their study investigating circulating plasma cells (sPCs) measured by 8 color flow cytometry in 402 multiple myeloma patients. Scope of these investigations is to evaluate the prognostic significance of cPCs, and also to define cut-offs for risk stratification.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH